
Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.
A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.
Welcome back to our recap of news and updates from the






